SynthesisBMC cardiovascular disorders2025

Effect of ABCG2 c.421 C> A (rs2231142) single nucleotide polymorphisms on the lipid-modulating efficacy of rosuvastatin: a meta-analysis.

Rosuvastatinno clear effectLower LDL cholesterol.Weak evidence: one subgroup.

What the trial testedrandomised · 1,347 people · 2025

One subgroup

−7.23−8.71 to −5.75

rosuvastatin vs CC, in patients harboring an A allele

As reported

difference −7.23, 95% CI −8.71 to −5.75 · the paper's word: low-density lipoprotein cholesterol

1,347people with dyslipidemia, in this paper

Among patients harboring an A allele, the trial randomly assignedassigned by chance

rosuvastatin

May have lowered LDL cholesterol−7.23

randomised · one subgroup

the abstract, start to end

… lipoprotein cholesterol (LDL-C) [MD = -7.23, 95% CI (-8.71, -5.75), …

← favours treatmentfavours comparator →

could be chance

Low-density lipoprotein cholesterolrosuvastatin vs CC, in patients harboring an A allele

−7.23−8.71 to −5.75

StatinsLipids

1 / 4